TYK2 is a key regulator of the surveillance of B lymphoid tumors

Journal of Clinical Investigation

Volumn 114, Issue 11, 2004, Pages 1650-1658

  Stoiber, Dagmar ^a   Kovacic, Boris ^a   Schuster, Christian ^a   Schellack, Carola ^a   Karaghiosoff, Marina ^b   Kreibich, Rita ^a   Weisz, Eva ^a   Artwohl, Michaela ^a   Kleine, Olaf C ^a   Muller, Mathias ^b   Baumgartner Parzer, Sabina ^a   Ghysdael, Jacques ^c   Freissmuth, Michael ^a   Sexl, Veronika ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^c INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; JANUS KINASE; JANUS KINASE 2; PROTEIN TYK2; RAG2 PROTEIN; STAT PROTEIN; STAT5 PROTEIN; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; NUCLEAR PROTEIN; PROTEIN KINASE TYK2; PROTEIN TYROSINE KINASE; RAG2 PROTEIN, HUMAN; RAG2 PROTEIN, MOUSE; TYK2 PROTEIN, HUMAN; TYK2 PROTEIN, MOUSE; V(D)J RECOMBINATION ACTIVATING PROTEIN 2;

ABELSON MURINE LEUKEMIA ONCOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LEUKEMIA; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER INCIDENCE; CARCINOGENESIS; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; GRAFT REJECTION; HOST; IMMUNOSURVEILLANCE; IN VITRO STUDY; KNOCKOUT MOUSE; LATENT PERIOD; LYMPHATIC SYSTEM TUMOR; MOUSE; NATURAL KILLER CELL; NEWBORN; NONHUMAN; PRIORITY JOURNAL; T CELL LEUKEMIA; ANIMAL; CANCER TRANSPLANTATION; CYTOLOGY; EXPERIMENTAL LEUKEMIA; GENETICS; HUMAN; IMMUNOLOGY; LIVER; METABOLISM; MOUSE MUTANT; NUDE MOUSE; PATHOLOGY; SPLEEN; SURVIVAL RATE;

ABELSON MURINE LEUKEMIA VIRUS; ANIMALS; ANIMALS, NEWBORN; CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; HUMANS; LEUKEMIA, B-CELL; LEUKEMIA, EXPERIMENTAL; LEUKEMIA, T-CELL; LIVER; MICE; MICE, KNOCKOUT; MICE, NUDE; NEOPLASM TRANSPLANTATION; NUCLEAR PROTEINS; PROTEIN-TYROSINE KINASES; SPLEEN; SURVIVAL RATE; TYK2 KINASE;

EID: 15244349726     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200422315     Document Type: Article

References (54)

1. Ihle, J.N. 2001. The STAT family in cytokine signaling. Curr. Opin. Cell Biol. 13:211-217.
2. O'Shea, J.J., Gadina, M., and Schreiber, R.D. 2002. Cytokine signalling in 2002: new surprises in the Jak/Stat pathway. Cell. 109:121-131.
3. Igaz, P., Toch, S., and Falus, A. 2001. Biological and clinical significance of the JAK-STAT pathway: lessons from knockout mice. Inflamm. Res. 50:435-441.
4. Yu, H., and Jove, R. 2004. The Stats of cancer: new molecular targets come of age. Nat. Rev. Cancer. 4:97-105.
5. Garcia, R., et al. 2001. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene. 20:2499-2513.
6. Gao, B.,et al. 2001. Constitutive activation of JAK-STAT3 signaling by BRCA1 in human prostate cancer cells. FEBS Lett. 488:179-184.
7. Frank, D.A., Mahajan, S., and Ritz, J. 1997. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J Clin. Invest. 100:3140-3148.
8. Coffer, P.J., Koenderman, L., and de Groot, R.P. 2000. The role of STATs in myeloid differentiation and leukaemia. Oncogene. 19:2511-2522.
9. Gouilleux-Gruart, V., et al. 1997. Activated STAT related transcription factors in acute leukaemia. Leuk. Lymphoma. 28:83-88.
10. Bromberg, J.F., et al. 1999. STAT3 as an oncogene. Cell. 98:295-303.
11. Kelly, J.A., et al. 2003. STATS synergizes with T cell receptor/antigen stimulation in the development of lymphoblastic lymphoma. J. Exp. Med. 198:79-89.
12. Danial, N.N., et al. 1998. Direct interaction of JAK1 and v-Abl is required for v-Abl-induced activation of STATs and proliferation. Mol. Cell. Biol. 18:6795-6804.
13. Zhang, Y., et al. 2000. Activation of STAT3 in v-Src-transformed fibroblasts requires cooperation of JAK1 kinase activity. J. Biol. Chem. 275:24935-24944.
14. Lacronique, V., et al. 1997. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science. 278:1309-1312.
15. Carron, C., et al. 2000. TEL-JAK2 transgenic mice develop T-cell leukemia. Blood. 95:3891-3899.
16. Sexl, V., et al. 2003. JAK1 deficiency leads to enhanced Abelson-induced B-cell tumor formation. Blood. 101:4937-4943.
17. Dunn, G.P., Bruce, A.T., Ikeda, H., Old, L.J., and Schreiber, R.D. 2002. Cancer immunoediring: from immuno-surveillance to tumor escape. Nat. Immunol. 3:991-998.
18. Kaplan, D.H., et al. 1998. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. U.S. A. 95:7556-7561.
19. Shankaran, V., et al. 2001. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 410:1107-1111.
20. Street, S.E., Cretney, E., and Smyth, M.J. 2001. Perforin an interferon-γ activities independently control tumor initiation, growth, and metastasis. Blood. 97:192-197.
21. Street, S.E., Trapani, J.A., MacGregor, D., and Smyth, M.J. 2002. Suppression of lymphoma and epithelial malignancies effected by interferon γ. J. Exp. Med. 196:129-134.
22. Stephanou, A., and Latchman, D.S. 2003. STAT-1: a novel regulator of apoptosis. Int. J. Exp. Pathol. 84:239-244.
23. Velazquez, L., Fellous, M., Stark, G.R., and Pellegrini, S. 1992. A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell. 70:313-322.
24. Schindler, C. 1999. Cytokines and JAK-STAT signaling. Exp. Cell Res. 253:7-14.
25. Karaghiosoff, M., et al. 2000. Partial impairment of cytokine responses in TYK2-deficient mice. Immunity. 13:549-560.
26. Shimoda, K., et al. 2000. TYK2 plays a restricted role in IFNα signaling, although it is required for IL-12-mediated T cell function. Immunity. 13:561-571.
27. Karaghiosoff, M., et al. 2003. Central role for type I interferons and TYK2 in lipopolysaccharide-induced endotoxin shock. Nat. Immunol. 4:471-477.
28. Abelson, H.T., and Rabstein, L.S. 1970. Influence of prednisolone on Moloney leukemogenic virus in BALB-c mice. Cancer Res. 30:2208-2212.
29. Rosenberg, N., and Witte, O.N. 1988. The viral and cellular forms of the Abelson (abl) oncogene. Adv. Virus Res. 35:39-81.
30. Faderl, S., et al. 1999. The biology of chronic myeloid leukemia. N. Engl. J. Med. 341:164-172.
31. Specchia, G., et al. 1995. Ph positive acute lymphoblastic leukaemia in adults: molecular and clinical studies. Leuk. Lymphoma. 18:37-42.
32. Peeters, P., et al. 1997. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood. 90:2535-2540.
33. Vallera, D.A., Taylor, P.A., Aukerman, S.L., and Blazar, B.R. 1993. Antitumor protection from the murine T-cell leukemia/lymphoma EL4 by the continuous subcutaneous coadministration of recombinant macrophage-colony stimulating factor and interleukin-2. Cancer Res. 53:4273-4280.
34. Visseren, M.J., et al. 1994. Production of interleukin-2 by EL4 tumor cells induces natural killer cell- and T-cell-mediated immunity. J. Immunother. Emphasis Tumor Immunol. 15:119-128.
35. Akamatsu, S., et al. 2002. Antitumor activity of interleukin-18 against the murine T-cell leukemia/ lymphoma EL-4 in syngeneic mice. J. Immunother. 25(Suppl. 1):S28-S34.
36. Bowman, T., Garcia, R., Turkson, J., and Jove, R. 2000. STATs in oncogenesis. Oncogene. 19:2474-2488.
37. Xie, S., Lin, H., Sun, T., and Arlinghaus, R.B. 2002. JAK2 is involved in c-Myc induction by Bcr-Abl. Oncogene. 21:7137-7146.
38. Lowdell, M.W., Lamb, L., Hoyle, C., Velardi, A., and Prentice, H.G. 2001. Non-MHC-restricted cytotoxic cells: their roles in the control and treatment of leukaemias. Br. J. Haematol 114:11-24.
39. Street, S.E., et al. 2004. Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and γδ T cells. J. Exp. Med. 199:879-884.
40. Baron, F., et al. 2002. Leukemic target susceptibility to natural killer cytotoxicity: relationship with BCR-ABL expression. Blood. 99:2107-2113.
41. Gruber, T.A., Skelton, D.C., and Kohn, D.B. 2002. Requirement for NK cells in CD40 ligand-mediated rejection of Philadelphia chromosome-positive acute lymphoblastic leukemia cells. J. Immunol. 168:73-80.
42. Inngjerdingen, M., Rolstad, B., and Ryan, J.C. 2003. Activating and inhibitory Ly49 receptors modulate NK cell chemotaxis to CXC chemokine ligand (CXCL) 10 and CXCL12. J. Immunol. 171:2889-2895.
43. Soriano, S.F., et al. 2002. Functional inactivation of CXC chemokine receptor 4-mediated responses through SOCS3 up-regulation. J. Exp. Med. 196:311-321.
44. Garcia-Lora, A., Algarra, I., and Garrido, F. 2003. MHC class I antigens, immune surveillance, and tumor immune escape. J. Cell. Physiol. 195:346-355.
45. Jager, E., et al. 1997. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int. J. Cancer. 71:142-147.
46. Shimoda, K., et al. 2002. Partial impairment of interleukin-12 (IL-12) and IL-18 signaling in TYK2-deficient mice. Blood. 99:2094-2099.
47. Kobayashi, M., et al. 1989. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 170:827-845.
48. Magram, J., et al. 1996. IL-12-deficient mice are defective in IFNγ production and type 1 cytokine responses. Immunity. 4:471-481.
49. Sexl, V., et al. 2000. STAT5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of stat5. Blood. 96:2277-2283.
50. Shinkai, Y., et al. 1992. Rag-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell. 68:855-867.
51. Szremska, A.P., et al. 2003. JunB inhibits proliferation and transformation in B-lymphoid cells. Blood. 102:4159-4165.
52. Stoiber, D., Stockinger, S., Steinlein, P., Kovarik, J., and Decker, T. 2001. Listeria monocytogenes modulates macrophage cytokine responses through STAT serine phosphorylation and the induction of suppressor of cytokine signaling 3. J. Immunol. 166:466-472.
53. Cerwenka, A., et al. 2000. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity. 12:721-727.
54. Decker, T., and Lohmann Mattes, M.L. 1988. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J. Immunol. Methods. 115:61-69.